<DOC>
	<DOCNO>NCT03081052</DOCNO>
	<brief_summary>The primary purpose study 2 aim . First , conduct clinical investigation determine iEPO , Veletri® similar efficacy pulmonary vasodilation similar impact compare iNO , INOMAX® adult patient undergo heart transplantation , lung transplantation implantation leave ventricular assist device . Second , conduct cost-capture analysis expense drug incurs per patient .</brief_summary>
	<brief_title>Inhaled Pulmonary Vasodilator Therapy Left Ventricular Assist Device ( LVAD ) Implantation , Heart Transplantation , Lung Transplantation : Prospective , Randomized , Double-Blinded Study</brief_title>
	<detailed_description>Inhaled Nitric Oxide ( iNO ) selective pulmonary vasodilator ( PVD ) FDA-approval neonatal population alone . In adult patient , iNO use off-label treat pulmonary hypertension , right ventricular ( RV ) failure , ventilation-to-perfusion mismatch . Adult patient undergo durable LVAD implantation ( e.g . Heartware® , Heartmate 2® , Heartmate 3® ) cardiac transplantation end-stage heart failure endure lung transplantation result end-stage lung disease , compose large subpopulation receive PVD therapy Duke University Hospital . Inhaled Epoprostenol ( iEPO ) introduce cardiothoracic operating room ( OR ) ICU cost-conscious alternative medication iNO . iEPO may display equivalent efficacy profile iNO pulmonary vasodilation oxygenation similar impact clinical outcome . 424 informed consent subject undergo thoracic transplantation leave ventricular assist device ( LVAD ) implantation care one investigator prospectively enrol three-year period ( one-year follow-up ) . Patients randomly assign 50/50 accord randomization stratum one two standard care pulmonary vasodilation therapy , iNO v iEPO . Additional study procedure involve data collection blood sampling .</detailed_description>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>Vasodilator Agents</mesh_term>
	<criteria>Thoracic ( heart lung ) transplantation patient LVAD implantation patient Combined Organ Transplantation ( HeartLung , HeartLiver , HeartKidney ) Age &lt; 18 year old Pregnancy Known allergy prostaglandin ( rare ) Subject enrol another study protocol , allow randomization PVD therapy Heart transplant durable LVAD recipient adult congenital heart disease ( CHD ) Caveat : Does NOT meet exclusion criterion schedule heart transplant LVAD implantation due heart failure previous heart transplantation relate CHD , perform 90 day previous date trial enrollment Patient schedule undergo lung transplantation undergone heart transplantation previous 90 day Patient schedule undergo durable LVAD implantation undergone heart transplantation previous 90 day Patient schedule undergo heart transplantation undergone lung transplantation previous 90 day Patients preoperative Venovenous ECMO bridge lung transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart Lung transplantation surgery</keyword>
	<keyword>Pulmonary vasodilation therapy</keyword>
</DOC>